{"indexed":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T22:49:19Z","timestamp":1574376559924},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"URL":"http:\/\/www.springer.com\/tdm","start":{"date-parts":[[2011,2,9]],"date-time":"2011-02-09T00:00:00Z","timestamp":1297209600000},"delay-in-days":0,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s00223-011-9468-2","type":"article-journal","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T07:14:59Z","timestamp":1297149299000},"page":"402-408","source":"Crossref","is-referenced-by-count":11,"title":"No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response","prefix":"10.1007","volume":"88","author":[{"given":"Polyzois","family":"Makras","sequence":"first","affiliation":[]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[]},{"given":"Ilias","family":"Bisbinas","sequence":"additional","affiliation":[]},{"given":"Grigorios T.","family":"Sakellariou","sequence":"additional","affiliation":[]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,2,9]]},"reference":[{"key":"9468_CR1","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380\u20134387","journal-title":"J Clin Endocrinol Metab"},{"key":"9468_CR2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S, Bhalla A, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V (1987) The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326\u2013331","journal-title":"Calcif Tissue Int"},{"key":"9468_CR3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","volume":"10","author":"DH Schweitzer","year":"1995","unstructured":"Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE (1995) Interleukin-6 and the acute phase response during treatment of patients with Paget\u2019s disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956\u2013962","journal-title":"J Bone Miner Res"},{"key":"9468_CR4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002239900353","volume":"61","author":"D Thiebaud","year":"1997","unstructured":"Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386\u2013392","journal-title":"Calcif Tissue Int"},{"key":"9468_CR5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","volume":"295","author":"HI Harinck","year":"1987","unstructured":"Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL (1987) Paget\u2019s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) 295:1301\u20131305","journal-title":"Br Med J (Clin Res Ed)"},{"key":"9468_CR6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","volume":"264","author":"E Beek van","year":"1999","unstructured":"van Beek E, Pieterman E, Cohen L, L\u00f6wik C, Papapoulos S (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108\u2013111","journal-title":"Biochem Biophys Res Commun"},{"key":"9468_CR7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1359\/jbmr.1999.14.5.722","volume":"14","author":"E Beek van","year":"1999","unstructured":"van Beek E, L\u00f6wik C, van der Pluijm G, Papapoulos S (1999) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14:722\u2013729","journal-title":"J Bone Miner Res"},{"key":"9468_CR8","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-06-0843","volume":"12","author":"AJ Roelofs","year":"2006","unstructured":"Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222\u20136230","journal-title":"Clin Cancer Res"},{"key":"9468_CR9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","volume":"144","author":"AJ Roelofs","year":"2009","unstructured":"Roelofs AJ, Jauhiainen M, M\u00f6nkk\u00f6nen H, Rogers MJ, M\u00f6nkk\u00f6nen J, Thompson K (2009) Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP. Br J Haematol 144:245\u2013250","journal-title":"Br J Haematol"},{"key":"9468_CR10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1359\/JBMR.0301230","volume":"19","author":"K Thompson","year":"2004","unstructured":"Thompson K, Rogers MJ (2004) Statins prevent bisphosphonate-induced gdT-cell proliferation and activation in vitro. J Bone Miner Res 19:278\u2013288","journal-title":"J Bone Miner Res"},{"key":"9468_CR11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.081016","volume":"24","author":"T Srivastava","year":"2009","unstructured":"Srivastava T, Haney CJ, Alon US (2009) Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate Infusion. J Bone Miner Res 24:334\u2013337","journal-title":"J Bone Miner Res"},{"key":"9468_CR12","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/art.1780231018","volume":"23","author":"OL Bijvoet","year":"1980","unstructured":"Bijvoet OL, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Mulder H, van Paassen HC, Reitsma PH, te Velde J, de Vries E, van der Wey JP (1980) APD in Paget\u2019s disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 23:1193\u20131204","journal-title":"Arthritis Rheum"},{"key":"9468_CR13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1359\/jbmr.090819","volume":"25","author":"F Bertoldo","year":"2010","unstructured":"Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, Valenti MT, Carbonare LD, Lo Cascio V (2010) Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 25:447\u2013454","journal-title":"J Bone Miner Res"},{"key":"9468_CR14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"9468_CR15","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","volume":"40","author":"K Saag","year":"2007","unstructured":"Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:1238\u20131243","journal-title":"Bone"},{"key":"9468_CR16","first-page":"235","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure\u2013activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"9468_CR17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.amjcard.2006.11.036","volume":"99","author":"JL P\u00e9rez-Castrill\u00f3n","year":"2007","unstructured":"P\u00e9rez-Castrill\u00f3n JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Due\u00f1as A (2007) Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 99:903\u2013905","journal-title":"Am J Cardiol"},{"key":"9468_CR18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10557-009-6181-8","volume":"23","author":"B Yavuz","year":"2009","unstructured":"Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, Kucukazman M, Dal K, Hokkaomeroglu MS, Yavuz BB, Tutal E (2009) Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 23:295\u2013299","journal-title":"Cardiovasc Drugs Ther"},{"key":"9468_CR19","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.5551\/jat.5652","volume":"17","author":"SS Yoon","year":"2010","unstructured":"Yoon SS, Dillon CF, Carroll M, Illoh K, Ostchega Y (2010) Effects of statins on serum inflammatory markers: the U.S. National Health and Nutrition Examination Survey 1999\u20132004. J Atheroscler Thromb 17:1176\u20131182","journal-title":"J Atheroscler Thromb"},{"key":"9468_CR20","unstructured":"Thompson K, Keech F, McLernon DJ, Vinod K, May RJ, Simpson WG, Rogers MJ, Reid DM (2010) Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone. doi: 10.1016\/j.bone.2010.10.177","DOI":"10.1016\/j.bone.2010.10.177","doi-asserted-by":"crossref"},{"key":"9468_CR21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1359\/jbmr.2003.18.1.88","volume":"18","author":"A Staal","year":"2003","unstructured":"Staal A, Frith JC, French MH, Swartz J, G\u00fcng\u00f6r T, Harrity TW, Tamasi J, Rogers MJ, Feyen JH (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18:88\u201396","journal-title":"J Bone Miner Res"}],"container-title":"Calcified Tissue International","original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-011-9468-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-011-9468-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-011-9468-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T11:52:11Z","timestamp":1559994731000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,9]]},"references-count":21,"journal-issue":{"published-print":{"date-parts":[[2011,5]]},"issue":"5"},"alternative-id":["9468"],"URL":"http:\/\/dx.doi.org\/10.1007\/s00223-011-9468-2","relation":{"cites":[]},"ISSN":["0171-967X","1432-0827"],"subject":["Endocrinology, Diabetes and Metabolism","Endocrinology","Orthopedics and Sports Medicine"],"container-title-short":"Calcif Tissue Int"}